Treatment of postherpetic neuralgia: focus on pregabalin

Kimberly A Cappuzzo
The Geriatric Pharmacotherapy Program, Virginia Commonwealth University, School of Pharmacy, Richmond, Virginia, USA

Abstract: Postherpetic neuralgia (PHN) is a devastating, chronic pain syndrome that can develop following an outbreak of herpes zoster and becomes increasingly common as patients age. PHN can be difficult to treat and often requires trials of multiple agents to achieve significant pain relief. Pregabalin is the newest agent to gain approval for PHN. Data suggest efficacy for relief of pain and sleep disturbance secondary to PHN in affected patients. Although there are no head-to-head comparisons, pregabalin appears comparable to gabapentin and other first-line agents for treating PHN.

Keywords: pregabalin, postherpetic neuralgia, neuropathic pain

Introduction

Herpes zoster (HZ) or shingles is a result of reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox. After the acute varicella infection (ie, chickenpox in childhood), the virus can lie dormant for decades in sensory nerve ganglia, usually involving the lumbar, thoracic and trigeminal ganglia. HZ results when dormant VZV in these nerves is reactivated, possibly secondary to a decline in specific cell-mediated immunity to VZV with aging and/or immunosuppression. The majority of cases of HZ are seen in older adults, with incidence increasing sharply at around 50 years of age and doubling by age 80.1,2 Neither gender, race, nor ethnicity appear to be risk factors for HZ.3

A patient with HZ may first develop a prodromal syndrome with fever, malaise, and pain that is generally localized to the affected dermatome. This pain may include burning, itching, and hypersensitivity and may precede the rash by 4 to 5 days.1,4 Because many patients initially present with severe pain as their chief complaint, patients are often misdiagnosed.

Pain is the major symptom of HZ, and, in most patients, the pain resolves spontaneously over time. However, about 10% to 15% of patients develop chronic, debilitating postherpetic pain that persists after the characteristic rash disappears2,5 with some patients experiencing persistent pain for years.6 Postherpetic neuralgia (PHN) is defined in the literature as pain that persists for more than 1 to 6 months after rash resolution. In most clinical trials, PHN is defined as pain persisting for more than 3 months after resolution of the rash.2,3,5

PHN is often characterized by a combination of throbbing or burning pain, intermittent sharp pains, altered sensory perception, including paresthesia, and allodynia (painful response to an innocuous stimulus).7 The pain may extend beyond the borders of the original zoster rash. The variety of symptoms likely result from injury to the dorsal root ganglia and dorsal horn as well as injury to the peripheral nerves. The incidence, duration, and severity are all related to increasing age; in fact, PHN is uncommon in those less than 60 years of age.1,4 Presence of pain prior to rash eruption,
rash severity, and inflammation and fever are thought to all have an effect on PHN severity. PHN pain is often severe, unrelenting, and exhausting. As a result, PHN can dramatically affect a patient’s quality of life and functional status. Patients may develop insomnia, weight loss, chronic fatigue, and an inability to perform daily activities. It is estimated that more than 50% of patients with PHN have sleep disturbances, and about 25% report a decrease in socialization. Eventually a patient with PHN may lose the ability for self-care, leading to depression and social isolation.

Successful management of PHN can be complicated and challenging, especially with the fact that there is no definitive treatment algorithm specifically for patients with PHN. In recent years, there have been a number of published guidelines proposed for the treatment of neuropathic pain in general. These recommendations are essentially based on evidence of efficacy from randomized controlled trials (RCTs) of pharmacologic therapies; there is a lack of clinical trials directly comparing efficacy and safety of one pharmacotherapy versus another. These guidelines uniformly recommend tricyclic antidepressants (TCAs), opioids, and anticonvulsants as first-line therapeutic options for treating neuropathic pain. First or second-line recommendations include topical treatments (eg, topical lidocaine), depending on the source.

Both gabapentin and pregabalin (PGB) are oral anticonvulsants approved for the management of PHN. They are both recommended as first-line therapeutic choices for neuropathic pain based on several RCTs. Although there have been no head-to-head RCTs between these 2 agents in patients with PHN, both have significantly reduced pain (p < 0.01) and improved sleep (p < 0.01).

This review will focus specifically on PGB, the newest agent to gain approval for PHN. A general overview of the drug will be given, followed by a review of clinical trial efficacy and adverse effects data in PHN patients, concluding with a discussion of PGB’s place in therapy in treating PHN.

**Pregabalin overview: pharmacology and pharmacokinetics**

PGB was first approved in the European Union by the European Agency for the Evaluation of Medicinal Products for the treatment of peripheral neuropathic pain in July 2004. PGB received conditional approval by the US Food and Drug Administration for the treatment of diabetic peripheral neuropathy (DPN) and PHN in December 2004 and was granted final approval after controlled substance scheduling by the US Drug Enforcement Agency in August 2005. PGB is a schedule V controlled substance based on a study with 15 recreational sedative/hypnotic drug users who rated the “desirability” of a single dose of PGB 450 mg as similar to a single dose of diazepam 30 mg. Indeed, euphoria was reported in 4% of PGB-treated patients versus 1% of placebo-treated patients in over 5500 patients in controlled clinical trials, and withdrawal symptoms suggestive of physical dependence were reported upon abrupt discontinuation of PGB in some studies.

The exact mechanism of action of PGB is unclear but is thought to be similar to that of gabapentin. PGB is a structural analogue of GABA, but it is inactive at GABA-A or -B receptors, it is not converted into GABA or a GABA antagonist, and it does not affect GABA uptake. PGB is an alpha2-delta ligand. PGB may alter the release of several neurotransmitters, by selectively binding to the alpha2-delta auxiliary protein subunit of voltage-gated calcium channels. By tightly binding to alpha2-delta protein, PGB reduces the influx of calcium, thereby reducing the release of neurotransmitters, including glutamate, norepinephrine, and substance P. These mechanisms are thought to result in the anticonvulsant, anxiolytic, and analgesic properties exhibited by PGB.

PGB was created in an attempt to develop a compound that would retain the biologic activity of gabapentin while improving its pharmacokinetic profile. PGB is well absorbed following oral administration with an oral bioavailability of ≥90%. The bioavailability of gabapentin actually decreases from 60% to 27% with increasing doses due to saturable absorption (900 mg/day versus 4800 mg/day, respectively). Unlike gabapentin, PGB exhibits linear pharmacokinetics. Elimination of PGB is virtually proportional to creatinine clearance (CrCl). Dosage adjustments for renal dysfunction are provided (Table 1). Ninety-eight percent of a dose of PGB is excreted unchanged in the urine, and the drug undergoes negligible metabolism with no anticipated CYP 450 enzyme drug interactions. PGB pharmacokinetics do not appear to be affected by race or gender and have not been studied in pediatric patients. Renal clearance of PGB appears to decrease with age, consistent with age-related changes in renal function. Hence, older adults often require renal adjustment of PGB dosing. PGB is effectively cleared by hemodialysis; 50%–60% is removed from the circulation following a 4-hour hemodialysis session. Therefore, a supplemental dose should be given immediately following every 4-hour hemodialysis treatment (Table 1).

**Literature review: pregabalin for PHN**

The efficacy of PGB for management of PHN has been demonstrated in 3 double-blind, placebo-controlled, multicenter...
clinical trials involving patients with PHN, and 1 randomized, double-blind, placebo-controlled study in patients with chronic neuropathic pain including PHN.7,14,18,25 Studies comparing PGB with other agents used to treat PHN are not available. Patients failing to respond to gabapentin were excluded from most of these studies.7,14,18 An important point to note: all 4 trials described herein were sponsored by the manufacturer of PGB (Pfizer), and the trials were conducted at least in part by Pfizer employees.

An 8-week trial was conducted in 173 patients with PHN, defined as pain persisting for >3 months following the healing of a HZ rash.14 Concomitant medications that were allowed at stable doses during the trial included opioid and non-opioid analgesics, NSAIDs, aspirin, acetaminophen (≤4 g/day), and antidepressants including SSRIs. Benzodiazepines, skeletal muscle relaxants, oral steroids, local and topical agents for PHN, and anticonvulsants were prohibited. Patients were randomized to either PGB (n = 89) or placebo (n = 84). Doses were given three times a day. Those on PGB received either 600 mg/day (CrCl > 60 mL/min) or 300 mg/day (CrCl 30–60 mL/min). This renal dosage adjustment is based on pharmacokinetic studies that demonstrated comparable steady-state concentrations of PGB, thus allowing these 2 subsets to be combined as a single PGB treatment arm for the purpose of pain relief assessment.14,15 Mean age of the patients was 71.5 years, with 82% of patients over 65 years of age, and the mean duration of PHN was 33.8 months. Patients were required to have an average daily pain score of at least 4 on an 11-point numerical rating scale. Patients treated with PGB had greater reductions in mean pain scores than those treated with placebo (3.60 versus 5.29; p < 0.0001). A decrease in pain was seen in PGB-treated patients as early as day 1 and maintained throughout the study. In addition, significantly more patients receiving PGB had ≥50% reduction in mean pain scores than those receiving placebo. As a secondary endpoint, daily sleep interference scores were measured for all study participants by assessing the degree to which pain interfered with sleep during the previous 24 hours on an 11-point numerical rating scale. A score of 0 indicates pain did not interfere with sleep, and a score of 10 indicates pain completely interfered with sleep. Sleep interference scores were recorded in subjects’ daily diaries upon awakening. Significant improvements in mean sleep interference scores (derived from subjects’ last 7 days of diary entries while receiving study drug) were observed. At study end, the mean sleep interference score was 1.93 in PGB-treated patients versus 3.51 in placebo-treated subjects (p = 0.0001).14

A second 8-week trial was conducted in 238 patients with PHN of >6 months in duration after the healing of the HZ rash.7 Concomitant medications that were allowed at stable doses during the study period included NSAIDs, acetaminophen, opioid and non-opioid analgesics, and antidepressants. Anticonvulsants and benzodiazepines had to be discontinued at least 14 days prior to receiving study medication. Patients with a CrCl ≤ 30 mL/min were excluded from the trial. Patients were randomized to either PGB 150 mg/day (n = 81), PGB 300 mg/day (n = 76), or placebo (n = 81). Doses were given three times a day. Mean age of the patients was similar to those in the study by Dworkin and colleagues (73.2 years, 71.3, and 71.9 years for the placebo, 150 mg/day, and 300 mg/day groups, respectively), and the mean duration of PHN ranged from 44.8 to 40.7 months for the placebo, 150 mg/day, and 300 mg/day groups respectively. Patients were required to have an average daily pain score of at least 4 on an 11-point numerical rating scale (0 = no pain; 10 = worst possible pain) during the 7-day baseline period. In addition, patients were required to have a score of ≥40 mm on the 100 mm VAS of the SF-MPQ at
baseline and at randomization. The primary efficacy point was the mean of the last 7 daily pain scores on the 11-point pain scale. Endpoint mean pain scores were significantly reduced for both PGB 150 mg/day and PGB 300 mg/day groups compared to placebo. Significant improvement in pain was noted as early as week 1 and maintained throughout the study. There appeared to be some additional pain relief from the 300 mg/day dose versus the 150 mg/day dose per the endpoint mean pain scores reported by the patients in each PGB group. Those receiving 300 mg/day of PGB reported a mean pain score of 4.76 as compared to a 5.14 mean pain score in those receiving 150 mg/day; patients on placebo reported a mean pain score of 6.33 (p = 0.0001 and 0.0002 for 300 mg/day and 150 mg/day versus placebo, respectively). A significantly larger proportion of patients in both treatment groups obtained a ≥50% reduction in mean pain score from baseline to study end point (26% on 150 mg/day [p = 0.006] and 28% on 300 mg/day [p = 0.003] versus 10% on placebo). As with the previous trial, daily sleep interference scores were recorded by study subjects in diaries using an 11-point numerical rating scale. Both doses of PGB significantly reduced weekly mean sleep interference scores versus placebo (3.13 for those on 150 mg/day [p = 0.0003], 2.81 for those on 300 mg/day [p = 0.0001] and 4.24 for those on placebo).7

A 13-week trial in 370 patients with PHN of ≥3 months’ duration following the healing of HZ lesions was conducted to evaluate the efficacy of twice daily PGB therapy.18 Stable medication regimens (defined as medications taken ≥30 days prior to study entry) of non-opioid analgesics (eg, paracetamol, noramidopyrine), opioids, anti-inflammatory medications, and antidepressants were allowed during the trial. Prohibited medications included long-acting benzodiazepines, skeletal muscle relaxants, steroids, and anticonvulsants, among others; these had to be discontinued at least 7 days prior to study entry. Patients with a CrCl ≤ 30 mL/min were excluded from the trial. Patients were randomized to 1 of 4 treatment groups: placebo (n = 93), 150 mg/day (n = 87), 300 mg/day (n = 98), and 600 mg/day (n = 90). Doses were divided twice daily. Because a 50% reduction in CrCl is expected to result in a doubling of PGB exposure, patients in the 600 mg/day group were stratified based on CrCl: patients with CrCl > 60 mL/min received 600 mg/day, and those patients with CrCl > 30 and ≤60 mL/min received 300 mg/day, a dosage believed to provide equivalent exposure to 600 mg/day in patients with CrCl > 60 mL/min, based on pharmacokinetic studies.18,26 Mean age of the patients was 70.7 years, with 82% of patients over 65 years of age, and the mean duration of PHN was 40.7 months. Patients were required to have an average daily pain score of at least 4 on an 11-point numerical rating scale (0 = no pain; 10 = worst possible pain) on at least 4 days during the 7-day baseline period. Additionally, patients were required to have a score of ≥40 mm on a 100 mm VAS at baseline and at randomization. Primary outcome measure was the endpoint mean pain score from the last 7 days of the patients’ daily pain diaries. As with the previous two trials discussed, this study assessed related sleep interference due to pain as a secondary outcome. Daily sleep interference scores were again recorded by study subjects in diaries using an 11-point numerical rating scale. At endpoint, PGB demonstrated significant dose-dependent improvement in mean pain scores and significant improvement in mean sleep interference versus placebo. Mean pain scores decreased in a dose-dependent fashion as follows: PGB 150 mg/day was 5.26, PGB 300 mg/day 5.07, PGB 600 mg/day 4.35, and these were all significantly lower versus the placebo mean pain score of 6.14 (p = 0.0077, 0.0008, and 0.0001, for PGB 150, 300, and 600 mg/day, respectively). Mean sleep interference scores showed a similar dose-dependent pattern: PGB 150 mg/day 3.07, PGB 300 mg/day 2.84, and PGB 600 mg/day 2.17, and these were all significantly lower than the placebo score of 4.10 (p = 0.0007, 0.0001, and 0.0001, for PGB 150, 300, and 600 mg/day, respectively). These improvements in pain and sleep were seen as early as Week 1 of treatment. Additionally, significantly more patients in the PGB-treated groups demonstrated a ≥50% reduction in pain from baseline than those on placebo (26.4%, 26.5%, 37.5%, and 7.5% in the PGB 150 mg/day, 300 mg/day, 300/600 mg/day, and placebo groups, respectively; p = 0.001 for each PGB group versus placebo). The number needed to treat (NNT) based on those with ≥50% reduction in pain from baseline for all PGB dosages combined was 4.4.18

A 12-week trial examined the efficacy and tolerability of flexible- and fixed-dose regimens of PGB versus placebo in patients with PHN and painful DPN.25 PHN patients had pain present for ≥3 months after the healing of the HZ rash. Unlike the previously discussed trials, patients who had previously taken gabapentin were permitted in the trial, regardless of dose or duration of exposure. Use of SSRIs, aspirin, short-acting benzodiazepines (for insomnia), and paracetamol was permitted during the trial. Medications that were prohibited include drugs commonly used to treat neuropathic pain (eg, skeletal muscle relaxants, capsaicin cream, opioids, benzodiazepines), anticonvulsants, non-SSRI antidepressants, and drugs that may cause retinotoxicity (eg, hydroxychloroquine, thioridazine). Prohibited drugs had to be discontinued at least 7 days prior to the baseline visit.
Adverse effects/tolerability

The most common adverse effects with PGB treatment noted in PHN trials were dizziness, somnolence, and peripheral edema. Other notable side effects commonly reported with PGB use include dry mouth, blurred vision, weight gain, ataxia, headache, “thinking abnormal,” and nausea. Dizziness and somnolence were the most common adverse effects leading to study withdrawal. Dizziness and somnolence occurred more frequently at higher doses and began shortly after starting PGB. Symptoms including insomnia, nausea, headache, and diarrhea were reported by some patients following abrupt withdrawal of PGB. Therefore, PGB should be tapered gradually over a minimum of 1 week rather than discontinued abruptly. Weight gain noted in clinical trials of PGB was not limited to patients with peripheral edema. Even though weight gain was related to dose and duration of exposure to PGB, it did not appear to be associated with gender, age, or baseline BMI. A higher incidence of weight gain and peripheral edema were noted in patients taking both PGB and a thiazolidinedione, compared with patients taking either agent alone. Hence, care should be taken when co-administering PGB and one of these agents. The package insert cautions about the use of PGB in heart failure patients with NYHA Class III or IV cardiac status, and there have been reports of heart failure decompensation in patients using PGB for neuropathic pain.

Place in therapy

As discussed previously, PGB and gabapentin share several advantages such as a lack of pharmacokinetic drug interactions and similar mechanism of action and efficacy. It is unclear if PGB has any clinical advantage over gabapentin, though, as there have been no direct comparisons done in clinical trials between the two drugs. Unlike gabapentin, PGB exhibits linear pharmacokinetics following oral administration with low intersubject variability, which results in a more predictable dose-response relationship, since plasma concentrations increase linearly with increasing dose. Additionally, because of the pharmacokinetic advantages PGB has over gabapentin, patients can be initiated and titrated up to a target dose more rapidly. A dose-response relationship was demonstrated in two of the PGB trials discussed. Based on clinical trial data presented here and recommendations in PGB product labeling, patients may see more improvements at higher doses and should be titrated up to 600 mg/day if they do not experience adequate relief at lower doses and can tolerate the higher PGB doses. Gabapentin has a cost advantage over PGB since gabapentin has a lower cost generic available, but the monthly cost of PGB is similar to generic gabapentin at the highest target doses of gabapentin. The long-term economic impact of PGB in treating PHN is unclear.

A recently-updated meta-analysis on treatments for all types of neuropathic pain provides an evidence-based treatment algorithm for peripheral neuropathic pain. PGB/gabapentin and
TCAs/selective serotonin-norepinephrine reuptake inhibitors (SNRIs) were considered essentially equivalent as drugs of first choice based on pooled NNT and number needed to harm (NNH) data from available RCTs. SNRIs show promise as potential therapies for other types of neuropathic pain, but clinical trial data to support their use for PHN are not yet available. If a patient has a contraindication to using a TCA, such as ischemic heart disease or cardiac conduction abnormalities, PGB/gabapentin would be preferred over a TCA. A subsequent cost-effectiveness analysis by Smith and Roberts largely agreed with the algorithm recommended by Finnerup et al suggesting that gabapentin/PGB and TCAs appeared to be reasonable first choices for PHN from both a clinical and economic standpoint in patients without coronary artery disease, while gabapentin/PGB were clearly favored in patients with coronary artery disease or who had other contraindications to using TCAs. Smith and Roberts also examined PGB and gabapentin data separately, and, they noted that, if treated separately, gabapentin appeared to be preferred over PGB due to higher side effect discontinuance rates in some trials. Another cost-effective analysis comparing desipramine, gabapentin, and PGB for the treatment of PHN in hypothetical older adults 60 to 80 years of age concluded that desipramine was more cost-effective than the other agents. However, the study only analyzed the use of these three agents in patients with no known ischemic heart disease or no cardiac conduction abnormalities.

It is important to note that many PHN patients require trials of different therapies to achieve adequate pain relief; in fact, they often require more than 1 agent to manage their pain. There is no clinical trial or cost-effectiveness data available on PGB used in combination therapy for PHN.

**Conclusion**

PHN is a devastating consequence of HZ that significantly affects patient quality of life. Despite positive findings with several drug classes, the very heterogeneous nature of PHN makes successful pain management difficult. The response to therapy may vary within a single patient as well as from patient to patient. Often, trials of more than 1 agent are necessary before adequate pain management is achieved. Regardless of which agent is tried first, due to the complexity of PHN symptoms, it is not surprising that a single agent may not provide adequate pain relief. Many patients require a combination of therapies each ideally targeting different pain mechanisms. Ultimately, though, each pain management regimen needs to be tailored to the individual patient.

PGB appears to be an efficacious, well-tolerated option for the treatment of PHN. PGB has some advantages over other available, recommended therapies, but cost may be an issue versus other established treatments. Additionally, long-term safety and efficacy of PGB still need to be established.

**Disclosures**

The author has no conflicts of interest to declare.

**References**
